血小板因子4(PF4)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Platelet Factor 4 (PF4) ,etc. by FLIA (Flow Luminescence Immunoassay)
CXCL4; SCYB4; Chemokine C-X-C-Motif Ligand 4; Oncostatin-A; Iroplact
（注：?jiǎn)未位鞙y(cè)多因子不超過(guò)8個(gè)指標(biāo) ）
- 編號(hào)LMA172Bo
- 物種Bos taurus; Bovine (Cattle，牛) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3.5h
- 檢測(cè)范圍0.39-400pg/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.13 pg/mL.
- 樣本類型Serum, platelet-poor plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說(shuō)明書 中文說(shuō)明書
- 規(guī)格 8指標(biāo)數(shù) 7指標(biāo)數(shù) 6指標(biāo)數(shù) 5指標(biāo)數(shù) 4指標(biāo)數(shù) 3指標(biāo)數(shù) 2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價(jià)格 ¥ 2830 ¥ 2939 ¥ 3102 ¥ 3320 ¥ 3537 ¥ 3864 ¥ 4354 ¥ 5442 添加到價(jià)格計(jì)算器 計(jì)算器
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)血小板因子4(PF4)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的血小板因子4(PF4)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 95-102 | 99 |
| EDTA plasma(n=5) | 86-101 | 96 |
| heparin plasma(n=5) | 93-105 | 101 |
| sodium citrate plasma(n=5) | 78-104 | 92 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的血小板因子4(PF4)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中血小板因子4(PF4)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 92-99% | 85-99% | 79-102% | 95-103% |
| EDTA plasma(n=5) | 78-101% | 81-90% | 87-101% | 81-95% |
| heparin plasma(n=5) | 93-101% | 92-102% | 87-94% | 87-99% |
| sodium citrate plasma(n=5) | 87-97% | 80-92% | 84-92% | 80-98% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品、樣本、磁珠）標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL，
37°C酶標(biāo)板振蕩器孵育90分鐘；
3. 磁吸甩干，加檢測(cè)溶液A100μL，37°C酶標(biāo)板振蕩器孵育60分鐘；
4. 磁吸洗板3次；
5. 加檢測(cè)溶液B100μL，37°C振動(dòng)孵育30分鐘；
6. 磁吸洗板3次；
7. 加鞘液100μL，旋渦震蕩2分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將血小板因子4(PF4)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體包被于磁珠，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠，其中的血小板因子4(PF4)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的血小板因子4(PF4)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體，將未結(jié)合的生物素化抗體洗凈后，加入PE標(biāo)記的親和素，再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的血小板因子4(PF4)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈(zèng)品
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Bos taurus; Bovine (Cattle，牛) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPA172Bo01 | 血小板因子4(PF4)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA172Bo01 | 血小板因子4(PF4)多克隆抗體 | WB; IHC; ICC; IP. |
| MAA172Bo21 | 血小板因子4(PF4)單克隆抗體 | WB; IHC; ICC; IP. |
| SEA172Bo | 血小板因子4(PF4)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA172Bo | 血小板因子4(PF4)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics | Propofol lowers serum PF4 level and partially corrects hypercoagulopathy in endotoxemic rats [PubMed: 20601223] |
| Basic Research in Cardiology | Secretome of apoptotic peripheral blood cells (APOSEC) attenuates microvascular obstruction in a porcine closed chest reperfused acute myocardial infarction model: role of platelet aggregation and vasodilation [PubMed: 22899170] |
| PLoS One | Platelets Recognize Brain-Specific Glycolipid Structures, Respond to Neurovascular Damage and Promote Neuroinflammation [PubMed: PMC3608633] |
| Diving and Hyperbaric Medicine | Effect of splenectomy on platelet activation and decompression sickness outcome in a rat model of decompression [Pubmed:25311322] |
| Journal of Functional Foods | A?Phellinus baumii–based supplement containing?Salvia miltiorrhiza?Bunge improves atherothrombotic profiles through endothelial nitric oxide synthase and cyclooxygenase pathwaysin vitro?and?in vivo [science:S1756464616300676] |
| Plos one | Aspirin, but Not Tirofiban Displays Protective Effects in Endotoxin Induced Lung Injury [pubmed:27583400] |
| international journal of molecular sciences | Evidence of the Role of R-Spondin 1 and Its Receptor Lgr4 in the Transmission of Mechanical Stimuli to Biological Signals for Bone Formation. [pubmed:28272338] |
| Experimental?and?Therapeutic?Medicine | Feasibility of improving platelet?rich plasma therapy by using chitosan with high platelet activation ability [pubmed:28450960] |
| Reproductive Toxicology | Aspirin pre-treatment modulates ozone-induced fetal growth restriction and alterations in uterine blood flow in rats [Pubmed: 30528429] |
| INTERNATIONAL JOURNAL OF CARDIOLOGY | Short and long-term changes in platelet and inflammatory biomarkers after cryoballoon and radiofrequency ablation [Pubmed: 30857843] |
| Available at SSRN 3335365? | Evaluating the Platelet Activation Related to the Degradation of Biomaterials by Scheme of Molecular Markers [] |
| journal of biotechnology | Newly Identified HNP‐F from Human Neutrophil Peptide 1 Promotes Hemostasis [Pubmed: 30927490] |
| Data in Brief | Data for short and long-term prothrombotic biomarkers after cryoballoon and radiofrequency ablation [] |
| journal of thoracic and cardiovascular surgery | Evaluating Platelet Activation Related to the Degradation of Biomaterials Using Molecular Markers [Pubmed: 32812629] |
| Marine Drugs | The Inhibitory Effect of Protamine on Platelets is Attenuated by Heparin without Inducing Thrombocytopenia in Rodents [Pubmed: 31533230] |
| Thrombosis Research | Feasibility study of use of rabbit blood to evaluate platelet activation by medical devices [Pubmed: 31838449] |
| Nat Commun | The C5a/C5a receptor 1 axis controls tissue neovascularization through CXCL4 release from platelets [34099640] |
| Vaccine | The effect of ChAdOx1 nCov-19 vaccine on arterial thrombosis development and platelet aggregation in female rats [Pubmed:35183388] |
